

February 10, 2024

Listing Department Code: 532321

BSE LIMITED

P J Towers, Dalal Street, Mumbai–400 001

Listing Department Code: ZYDUSLIFE

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), <u>Mumbai–400 051</u>

Re.: Newspaper publication

Dear Sir / Madam,

Please find attached the newspaper cutting with regard to publication of extracts of unaudited financial results for the quarter / nine months ended on December 31, 2023 in Financial Express on February 10, 2024.

Please find the same in order.

Thanking you,

Yours faithfully, For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI COMPANY SECRETARY

Encl.: As above

FINANCIAL EXPRESS



Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),

Near Valshnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481 Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com

CIN : 124220C1100EDLC02E020

100	Extract of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2023 Rupees in Million									
Sr. No	Particulars DEPTHEN ASIGN FARDERS TWO ST	3 Months ended 31/12/2023	Months ended	Corresponding 3 Months ended 31/12/2022 in the previous	Year to date figures for the current	Year to date figures for the previous period ended	Previous year			
1	Total income from operations	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)			
2	Net Profit for the period before exceptional items and tax	45,052	43,688	42,571	140,136	122,269	172,374			
3	Net Profit for the period after exceptional items but before tax	9,255	10,072	7,801	32,761	21,068	31,939			
4	Net Profit for the period from continuing operations	9,255	10,072	7,801	32,619	21,039	25,897			
5	Profit/ [Loss] after the feet of	7,678	8,017	6,225	26,574	16,661	19,649			
6	Profit/ [Loss] after tax from discontinued operations Net Profit for the period and	218	(10)	4	198	(24)				
7	Net Profit for the period after tax and Non-Controlling Interest Total Comprehensive Inc.	7,896	8,007	6,229	26,772	16,637	19,603			
8	Total Comprehensive Income for the period after tax and Non-Controlling Interest	8,099	7,446	5,479	26,476	13,444	16,459			
9	Paid-up equity share capital (Face value Re. 1/-)	1,012	1,012	1,012	1,012	1,012	1,012			
10	Reserves excluding Revaluation Reserve (i.e. Other Equity) Earnings per share for continuing operations (not annualised for the quarter and nine months)	Monote L					174,146			
	Basic (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35			
	Diluted (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35			
	Earnings per share for continuing & discontinued operations (not annualised for the quarter and nine months)	The Election				Ara m	19.55			
a	Dasic (Ks.)	7.80	7.91	6.15	26.45	16.36	19.30			
Note:	Diluted (Rs.)	7.80	7.91	6.15	26.45	16.36	19.30			

[1] The above is an extract of the detailed format of Quarterly/ Nine Monthly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/ Nine Monthly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

> By Order of the Board, For Zydus Lifesciences Limited,

Dr. Sharvil P. Patel Managing Director DIN: 00131995

Date: February 9, 2024 Place: Ahmedabad

इायनान्सियस એક्सप्रेस



Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481

Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com

	Extract of Consolidated Unaudited Financial Results for the Quarte	Rupees in Million							
Sr. No.	Particulars	3 Months ended 31/12/2023	Months ended	3 Months ended 31/12/2022 in the previous	The second secon	Year to date figures for the previous period ended	Previous year ended 31/03/2023		
100	Total income from operations	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)		
	and profit for the period before exceptional items and a	45,052	43,688	42,571	140,136	122,269	172,374		
	Net profit for the period after exceptional items but here.	9,255	10,072	7,801	32,761	21,068	31,93		
	Net Profit for the period from continuing operations	9,255	10,072	7,801	32,619	21,039	25,89		
100	orefit (Loss) after tax from discontinued operations	7,678	8,017	6,225	26,574	16,661	19,64		
		218	(10)		198	(24)	(4		
	Total Comprehensive Income for the period after tax and Non-Controlling Interest paids in equity share capital (Face value Re. 1/-)	7,896	8,007	6,229	26,772	16,637	19,60		
		8,099	7,446	5,479	26,476	13,444	16,45		
1000	a well reling Revaluation Reserve (Le Out	1,012	1,012	1,012	1,012	1,012	1,01		
	Earnings per share for continuing operations (not annualised for the quarter and nine months)		100		SIE DIETA		174,14		
a	Basic (Rs.)	MESTERS OF THE	州三年为中国		The Control of the Co				
b	Diluted (Rs.)	7.59	7.92	6.15	26.25	16.39	19.3		
8	Earnings per share for continuing & discontinued operations (not annualised for the quarter and nine months) Basic (Rs.)	7.59	7.92	6.15	26.25	16.39	19.3		
1750	Diluted (Rs.)	7.80	7.91	6.15	26,45	16.36	19.3		
e:		7.80	7.91	6.15	26,45	16.36	19.3		

Note:

[1] The above is an extract of the detailed format of Quarterly/ Nine Monthly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure of the Computer of t Requirements) Regulations, 2015. The full format of the Quarterly/ Nine Monthly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

> By Order of the Board, For Zydus Lifesciences Limited,

Date: February 9, 2024 Place: Ahmedabad

Dr. Sharvil P. Patel Managing Director DIN: 00131995